| Bioactivity | Lipid M (pKa: 6.75) can be used to deliver mRNA vaccine and yield a robust immune response with improved tolerability[1]. |
| In Vivo | Lipid M (50 μL containing 2 μg of luciferase mRNA formulated in LNPs, i.m.) is followed by rapid clearance in muscle, spleen and liver in CD-1 mice[1].Lipid M (300 μL containing 500 μg IgG mRNA formulated in LNPs, i.m.) yields serum antibody expression comparable to that of MC3-based LNPs in cynomolgus monkeys[1]. |
| Name | Lipid M |
| CAS | 2089251-57-8 |
| Formula | C44H87NO5 |
| Molar Mass | 710.17 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hassett KJ, et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol Ther Nucleic Acids. 2019 Apr 15;15:1-11. |